These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8470843)

  • 1. The choice of thrombolytic agents in the emergency department.
    Langland-Orban B; Orban DJ
    Ann Emerg Med; 1993 May; 22(5):845-51. PubMed ID: 8470843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy.
    Brody B; Wray N; Bame S; Ashton C; Petersen N; Harward M
    Med Care; 1991 Sep; 29(9):899-910. PubMed ID: 1921539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of streptokinase, urokinase, and recombinant tissue plasminogen activator in an in vitro model of venous thrombolysis.
    Ouriel K; Welch EL; Shortell CK; Geary K; Fiore WM; Cimino C
    J Vasc Surg; 1995 Nov; 22(5):593-7. PubMed ID: 7494361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
    Lessler DS; Avins AL
    Arch Intern Med; 1992 Aug; 152(8):1665-72. PubMed ID: 1497400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional thrombolytic infusion for peripheral arterial occlusion: is urokinase really the drug of choice?
    Weber JJ; Chong K
    Am J Health Syst Pharm; 1998 Nov; 55(22):2414-6. PubMed ID: 9825039
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
    Mark DB; Hlatky MA; Califf RM; Naylor CD; Lee KL; Armstrong PW; Barbash G; White H; Simoons ML; Nelson CL
    N Engl J Med; 1995 May; 332(21):1418-24. PubMed ID: 7723799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.
    Wang Y; Wu D; Zhao X; Ma R; Guo X; Wang C; Liu L; Zhao W; Wang Y
    Surg Neurol; 2009 Aug; 72 Suppl 1():S2-7. PubMed ID: 18423545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.
    Woo KS; White HD
    Pharmacoeconomics; 1993 Mar; 3(3):192-204. PubMed ID: 10172049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
    Sherry S; Marder VJ
    J Am Coll Cardiol; 1991 Nov; 18(6):1579-82. PubMed ID: 1939964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability in thrombolytic practice in Oregon.
    Young GP; Hedges JR; Collings JL
    Ann Emerg Med; 1991 Mar; 20(3):293-6. PubMed ID: 1996825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost-benefit study of different thrombolytic strategies in treating 156 patients with symptomatic pulmonary thromboembolism].
    Li XS; Deng XY; Liu HL
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Jun; 24(6):355-6. PubMed ID: 22681664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical decision making in the choice of a thrombolytic agent for acute myocardial infarction. Quebec Acute Coronary Care Working Group.
    Brophy JM; Joseph L; Theroux P
    Med Decis Making; 1999; 19(4):411-8. PubMed ID: 10520679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
    Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ
    JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of thrombolytic therapy in patients presenting to a peripheral metropolitan emergency department with acute myocardial infarction.
    Jacobs IG; Fatovich DM
    Aust N Z J Med; 1996 Aug; 26(4):539-42. PubMed ID: 8873938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombolytic drugs in acute myocardial infarct].
    Ambrosioni E; Degli Esposti D
    Cardiologia; 1991 Dec; 36(12 Suppl 1):395-402. PubMed ID: 1841796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
    Popma JJ; Califf RM; Ellis SG; George BS; Kereiakes DJ; Samaha JK; Worley SJ; Anderson JL; Stump D; Woodlief L
    J Am Coll Cardiol; 1992 Nov; 20(6):1305-12. PubMed ID: 1430679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.